[Report Overview and Operational Highlights](index=1&type=section&id=Report%20Overview%20and%20Operational%20Highlights) This section highlights the company's significant progress in 2022, detailing advancements in breast and pancreatic cancer programs and strategic paths toward registrational studies [CEO's Statement](index=1&type=section&id=CEO's%20Statement) The CEO highlighted significant progress in 2022, establishing clear, de-risked paths toward registrational studies for pelareorep in both breast and pancreatic cancer - The company has established clear and de-risked paths to registrational studies for pelareorep in both breast and pancreatic cancer[2](index=2&type=chunk) - The upcoming BRACELET-1 readout in **Q2 2023** is a key inflection point, expected to show pelareorep-based regimens outperforming paclitaxel monotherapy, which would accelerate advancement into a registrational trial and enhance business development[2](index=2&type=chunk) - Interim data from the GOBLET trial in pancreatic cancer showed an objective response rate **nearly three times greater** than historical controls, establishing it as a second core pillar of the company's pipeline[2](index=2&type=chunk) [Pancreatic Cancer Program](index=1&type=section&id=Pancreatic%20Cancer%20Program) The pancreatic cancer program showed highly promising results in the Phase 1/2 GOBLET trial, with a 69% objective response rate and FDA Fast Track designation - In the GOBLET trial's PDAC cohort, treatment with pelareorep, atezolizumab, gemcitabine, and nab-paclitaxel resulted in a **69% objective response rate (ORR)** among 13 evaluable patients, including one confirmed complete response[3](index=3&type=chunk) - The reported **69% ORR** is nearly three times the average **~25% ORR** from historical control trials using gemcitabine plus nab-paclitaxel[3](index=3&type=chunk) - The FDA granted **Fast Track designation** for pelareorep for the treatment of advanced/metastatic PDAC, which allows for more frequent FDA meetings and potential for Accelerated Approval and Priority Review[5](index=5&type=chunk) [Breast Cancer Program](index=2&type=section&id=Breast%20Cancer%20Program) The breast cancer program is advancing with positive interim data from a bridging trial and anticipates a key data readout from the BRACELET-1 trial in Q2 2023 - Interim results from Adlai Nortye's bridging trial in China showed that among 14 evaluable patients, **13 achieved disease control**, and **7 achieved a partial response** One patient maintained a partial response at week 48[6](index=6&type=chunk) - The combination of pelareorep and paclitaxel was well tolerated, with no dose-limiting toxicities or serious adverse events reported in the bridging trial[6](index=6&type=chunk) - Oncolytics expects to announce overall response rate and progression-free survival data from the randomized Phase 2 BRACELET-1 trial in **Q2 2023**[7](index=7&type=chunk) [Financial Highlights and Results](index=2&type=section&id=Financial%20Highlights%20and%20Results) This section details the company's financial performance for 2022, including cash position, net loss, and changes in financial statements [Fourth Quarter and Full Year 2022 Financial Summary](index=2&type=section&id=Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Summary) Oncolytics ended 2022 with $32.1 million in cash, projecting a runway into 2024, with a reduced net loss compared to 2021 - As of December 31, 2022, the company had **$32.1 million** in cash, cash equivalents, and marketable securities, providing a projected runway through the BRACELET-1 readout and into **2024**[1](index=1&type=chunk)[8](index=8&type=chunk) Full Year 2022 vs 2021 Financial Performance (CAD) | Metric | 2022 | 2021 | | :--- | :--- | :--- | | Net Loss | $24.8 million | $26.3 million | | Loss Per Share (basic and diluted) | $0.43 | $0.49 | | Net Cash Used in Operating Activities | $23.4 million | $22.4 million | | General & Administrative Expenses | $11.5 million | $13.3 million | | Research & Development Expenses | $15.4 million | $12.9 million | [Consolidated Statements of Financial Position](index=4&type=section&id=Consolidated%20Statements%20of%20Financial%20Position) The company's total assets decreased to $37.3 million by year-end 2022, primarily due to reduced cash, while liabilities slightly increased Consolidated Financial Position (in thousands of CAD) | As at December 31, | 2022 | 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $11,666 | $41,262 | | Total current assets | $35,684 | $44,904 | | **Total assets** | **$37,334** | **$45,880** | | Total current liabilities | $3,945 | $2,690 | | **Total liabilities** | **$10,832** | **$9,781** | | **Total shareholders' equity** | **$26,502** | **$36,099** | [Consolidated Statements of Loss and Comprehensive Loss](index=5&type=section&id=Consolidated%20Statements%20of%20Loss%20and%20Comprehensive%20Loss) For 2022, the company reported a net loss of $24.8 million, an improvement from 2021, influenced by lower G&A and a foreign exchange gain Consolidated Loss (in thousands of CAD) | For the years ended December 31, | 2022 | 2021 | | :--- | :--- | :--- | | Research and development | $15,432 | $12,920 | | General and administrative | $11,492 | $13,315 | | Foreign exchange gain (loss) | $1,665 | $(136) | | **Net loss** | **$(24,835)** | **$(26,304)** | | **Basic and diluted loss per common share** | **$(0.43)** | **$(0.49)** | [Consolidated Statements of Changes in Equity](index=6&type=section&id=Consolidated%20Statements%20of%20Changes%20in%20Equity) Total shareholders' equity decreased to $26.5 million by year-end 2022, primarily due to the net loss, partially offset by equity raised Changes in Shareholders' Equity (in thousands of CAD) | Description | 2022 | 2021 | | :--- | :--- | :--- | | Equity at Start of Year | $36,099 | $24,752 | | Net loss and other comprehensive income/loss | $(24,561) | $(26,316) | | Proceeds from "At the Market" Agreement | $13,338 | $34,168 | | **Equity at End of Year** | **$26,502** | **$36,099** | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities increased slightly in 2022, with significant cash used in investing activities, leading to a net decrease in cash Cash Flow Summary (in thousands of CAD) | For the years ended December 31, | 2022 | 2021 | | :--- | :--- | :--- | | Cash used in operating activities | $(23,355) | $(22,433) | | Cash used in investing activities | $(20,403) | $(286) | | Cash provided by financing activities | $12,205 | $33,015 | | **(Decrease) increase in cash and cash equivalents** | **$(31,553)** | **$10,296** | | **Cash and cash equivalents, end of year** | **$11,666** | **$41,262** | [Outlook and Future Milestones](index=3&type=section&id=Outlook%20and%20Future%20Milestones) This section outlines key anticipated milestones and catalysts for 2023, focusing on clinical program advancements and regulatory guidance [2023 Anticipated Milestones and Catalysts](index=3&type=section&id=2023%20Anticipated%20Milestones%20and%20Catalysts) Oncolytics has outlined several key milestones for 2023, including pivotal data readouts and guidance on registration paths for its clinical programs - Key anticipated milestones for 2023 include: * **Q2 2023:** Data readout (ORR, PFS, OS) from the Phase 2 BRACELET-1 metastatic breast cancer study * **Q2 2023:** Preclinical data from the combination of pelareorep and CAR T therapy * **H2 2023:** Updated data from the GOBLET study in advanced/metastatic PDAC * **H2 2023:** Updates on other cohorts (colorectal, anal) from the GOBLET study * **H2 2023:** Guidance on registration paths for both HR+/HER2- metastatic breast cancer and advanced/metastatic PDAC[12](index=12&type=chunk) [Company Information and Forward-Looking Statements](index=8&type=section&id=Company%20Information%20and%20Forward-Looking%20Statements) This section provides an overview of Oncolytics Biotech Inc. and includes important disclaimers regarding forward-looking statements and associated risks [About Oncolytics Biotech Inc.](index=8&type=section&id=About%20Oncolytics%20Biotech%20Inc.) Oncolytics Biotech is a biotechnology company developing pelareorep, an immunotherapeutic agent, for metastatic breast cancer and pancreatic cancer - Oncolytics is developing pelareorep, an intravenously delivered immunotherapeutic agent designed to induce anti-cancer immune responses[23](index=23&type=chunk) - The company is advancing towards registration studies in metastatic breast cancer and pancreatic cancer, with clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies[24](index=24&type=chunk) [Forward-Looking Statements](index=8&type=section&id=Forward-Looking%20Statements) This report contains forward-looking statements subject to risks and uncertainties, including clinical trial success and regulatory processes - The press release includes forward-looking statements concerning pelareorep's potential, clinical trial timing, regulatory plans, and business development[25](index=25&type=chunk) - Investors are cautioned that these statements involve risks and uncertainties, such as the availability of funds, clinical trial success, and potential business interruptions from events like the COVID-19 pandemic[25](index=25&type=chunk)

Oncolytics Biotech, Inc. (NASDAQ:ONCY) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Jon Patton - Director, IR & Communication Matt Coffey - CEO Tom Heineman - CMO Andrew de Guttadauro - Global Head, Business Development Kirk Look - CFO Conference Call Participants John Newman - Canaccord Operator Good morning, and welcome to Oncolytics Biotech's Third Quarter 2022 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session ...

[Condensed Interim Consolidated Financial Statements](index=2&type=section&id=Condensed%20Interim%20Consolidated%20Financial%20Statements) [Statements of Financial Position](index=2&type=section&id=Condensed%20Interim%20Consolidated%20Statements%20of%20Financial%20Position) The company's total assets decreased to $39.0 million, driven by lower cash, while liabilities increased and shareholders' equity declined Consolidated Statements of Financial Position (unaudited) | As at | September 30, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Total current assets** | $38,205,271 | $44,903,899 | | **Total assets** | **$38,958,977** | **$45,880,191** | | **Total current liabilities** | $3,666,145 | $2,689,838 | | **Total liabilities** | $10,562,350 | $9,781,206 | | **Total shareholders' equity** | $28,396,627 | $36,098,985 | | **Total liabilities and shareholders' equity** | **$38,958,977** | **$45,880,191** | [Statements of Loss and Comprehensive Loss](index=3&type=section&id=Condensed%20Interim%20Consolidated%20Statements%20of%20Loss%20and%20Comprehensive%20Loss) The company's net loss for the nine-month period improved to $16.3 million from $18.6 million year-over-year due to lower expenses and a foreign exchange gain Statement of Loss Highlights (Nine Months Ended September 30) | Metric | 2022 | 2021 | | :--- | :--- | :--- | | Research and development expenses | $10,590,464 | $9,240,900 | | General and administrative expenses | $7,825,659 | $9,539,188 | | Foreign exchange gain | $1,939,468 | $190,164 | | **Net loss** | **($16,280,513)** | **($18,553,023)** | | **Net comprehensive loss** | **($15,945,620)** | **($18,546,798)** | | **Basic and diluted loss per common share** | **($0.28)** | **($0.35)** | [Statements of Changes in Equity](index=4&type=section&id=Condensed%20Interim%20Consolidated%20Statements%20of%20Changes%20in%20Equity) Shareholders' equity decreased to $28.4 million, primarily driven by a net comprehensive loss partially offset by proceeds from financing activities - Total shareholders' equity decreased by **$7.7 million** during the first nine months of 2022, from $36.1 million to $28.4 million[7](index=7&type=chunk) - The decrease was primarily due to a **net comprehensive loss of $15.9 million**[7](index=7&type=chunk) - Financing activities, mainly from the "At the Market" Agreement, contributed **$7.2 million** to share capital[7](index=7&type=chunk) - Equity warrants with a book value of **$3.6 million** expired and were transferred to Contributed Surplus[7](index=7&type=chunk) [Statements of Cash Flows](index=5&type=section&id=Condensed%20Interim%20Consolidated%20Statements%20of%20Cash%20Flows) Cash and cash equivalents decreased by $11.1 million to $32.4 million, reflecting cash used in operations partially offset by financing inflows Cash Flow Summary (Nine Months Ended September 30) | Activity | 2022 | 2021 | | :--- | :--- | :--- | | Cash used in operating activities | ($17,416,436) | ($16,098,335) | | Cash used in investing activities | ($55,740) | ($211,236) | | Cash provided by financing activities | $6,334,841 | $33,067,387 | | **(Decrease) increase in cash** | **($11,137,335)** | **$16,757,816** | | **Cash and cash equivalents, end of period** | **$32,362,063** | **$48,087,369** | [Notes to Condensed Interim Consolidated Financial Statements](index=6&type=section&id=Notes%20to%20Condensed%20Interim%20Consolidated%20Financial%20Statements) [Note 1: Nature of Operations](index=6&type=section&id=Note%201%3A%20Nature%20of%20Operations) The company is a clinical-stage biopharmaceutical firm with a significant accumulated deficit but believes its current cash position is sufficient for the next year - The company is a clinical-stage biopharmaceutical firm developing pelareorep, an intravenously delivered immunotherapeutic agent for cancer[10](index=10&type=chunk) - Primary focus is advancing its program in HR+/HER2- metastatic breast cancer to a phase 3 study[10](index=10&type=chunk) - The company has an accumulated deficit of **$409,696,122** as of September 30, 2022, and has historically funded operations through equity issuance[11](index=11&type=chunk) - As of September 30, 2022, the company had cash and cash equivalents of **$32,362,063**, which is believed to be sufficient to fund operations for at least the next twelve months[12](index=12&type=chunk) [Note 5: Share Capital](index=8&type=section&id=Note%205%3A%20Share%20Capital) Share capital increased to $398.1 million due to share issuance via its ATM equity agreements, while a significant number of warrants expired Share Capital Reconciliation | Description | Number of Shares | Amount | | :--- | :--- | :--- | | **As at December 31, 2021** | **55,043,789** | **$391,348,183** | | Issued pursuant to ATM agreement | 3,613,760 | $7,159,552 | | Issued pursuant to stock option/incentive plan | 48,893 | $117,958 | | Share issue costs | — | ($557,389) | | **As at September 30, 2022** | **58,706,442** | **$398,068,304** | - The company utilized three separate "At the Market" (ATM) equity distribution agreements to raise capital, with the most recent one for up to **US$65 million** established in June 2022[27](index=27&type=chunk) - Equity warrants for **16,443,500 common shares** expired on June 1, 2022, and their value of $3,617,570 was transferred from Warrants to Contributed Surplus[28](index=28&type=chunk)[29](index=29&type=chunk) [Note 6: Share-Based Compensation](index=9&type=section&id=Note%206%3A%20Share-Based%20Compensation) Share-based compensation expense decreased to $1.6 million year-over-year, with approximately 5.3 million stock options outstanding at period end Stock Option Activity (Nine Months Ended Sept 30) | Activity | 2022 | 2021 | | :--- | :--- | :--- | | Outstanding, beginning of period | 5,334,420 | 3,764,055 | | Granted | 292,500 | 1,267,500 | | Forfeited/Expired/Exercised | (327,189) | (189,594) | | **Outstanding, end of period** | **5,299,731** | **4,841,961** | - Total share-based compensation expense for the nine months ended September 30, 2022, was **$1,629,016**, compared to $2,697,238 for the same period in 2021[34](index=34&type=chunk) [Note 8: Commitments](index=10&type=section&id=Note%208%3A%20Commitments) The company has future commitments of approximately $16.8 million for clinical trials and manufacturing, plus lease obligations - The company is committed to payments of approximately **$16,800,000** over the next three years for clinical trials, manufacturing, and science programs[36](index=36&type=chunk) - Commitments include the jointly funded BRACELET-1 phase 2 clinical trial with Pfizer[37](index=37&type=chunk) Total Undiscounted Lease Liability (as at Sept 30, 2022) | Period | Amount | | :--- | :--- | | Less than one year | $340,272 | | One to five years | $211,244 | | **Total** | **$551,516** | [Note 9: Capital Disclosures](index=11&type=section&id=Note%209%3A%20Capital%20Disclosures) The company manages capital primarily through equity issuance, renewing its $150 million base shelf prospectus and a US$65 million ATM agreement - The company's objective is to maintain a strong statement of financial position to support its clinical trial program, manufacturing, and other costs[41](index=41&type=chunk) - Funding is primarily managed through the issuance of additional common shares and warrants[44](index=44&type=chunk) - In June 2022, the company renewed its Base Shelf prospectus to qualify for the distribution of up to **$150,000,000** of securities until July 2024[45](index=45&type=chunk)[46](index=46&type=chunk) - The Base Shelf allowed the company to enter into a **US$65,000,000** ATM equity distribution agreement in June 2022[47](index=47&type=chunk) [Note 10: Financial Instruments](index=12&type=section&id=Note%2010%3A%20Financial%20Instruments) The company is exposed to various financial risks, with a primary foreign exchange risk related to its net U.S. dollar position of US$20.0 million - The company is exposed to credit risk, interest rate risk, foreign exchange risk, and liquidity risk[49](index=49&type=chunk)[51](index=51&type=chunk)[53](index=53&type=chunk)[56](index=56&type=chunk) - Foreign exchange risk is primarily from the U.S. dollar. A **$0.01 increase in the USD** against the CAD would have decreased the net comprehensive loss in 2022 by approximately **$188,000**[53](index=53&type=chunk) Significant Balances in Foreign Currencies (Sept 30, 2022) | Currency | Amount | | :--- | :--- | | **U.S. dollars** | | | Cash and cash equivalents | $21,377,467 | | Accounts payable and accrued liabilities | ($1,345,402) | | **Net U.S. dollar position** | **$20,032,065** | | **Euro** | | | Accounts payable and accrued liabilities | (€705,472) | [Note 12: Components of Expenses](index=14&type=section&id=Note%2012%3A%20Components%20of%20Expenses) R&D expenses increased to $10.6 million due to higher trial costs, while G&A expenses decreased to $7.8 million on lower public company costs Components of Expenses (Nine Months Ended September 30) | Expense Category | 2022 | 2021 | | :--- | :--- | :--- | | **Research and development** | **$10,590,464** | **$9,240,900** | | Clinical trial expenses | $3,674,955 | $2,576,886 | | Personnel-related expenses (R&D) | $3,592,412 | $2,906,119 | | **General and administrative** | **$7,825,659** | **$9,539,188** | | Public company related expenses | $4,787,000 | $6,066,646 | | Share-based compensation (G&A) | $718,043 | $1,226,669 | [Note 13: Related Party Transactions](index=14&type=section&id=Note%2013%3A%20Related%20Party%20Transactions) Key management personnel compensation decreased to $3.5 million from $4.2 million year-over-year, driven by lower share-based compensation Compensation of Key Management Personnel (Nine Months Ended September 30) | Compensation Type | 2022 | 2021 | | :--- | :--- | :--- | | Compensation and short-term benefits | $2,405,350 | $2,320,516 | | Share-based compensation | $1,128,096 | $1,869,090 | | **Total** | **$3,533,446** | **$4,189,606** |

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q2 2022 Results Conference Call August 11, 2022 8:30 AM ET Company Participants Jon Patton - Director of Investor Relations and Communications Matthew Coffey - President and Chief Executive Officer Kirk Look - Chief Financial Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - President Conference Call Participants Jason Kolber - HC Wainwright Operator Good afternoon, and welcome to Oncolytics BiotechÂ's Second Quarter 2022 Conference Call. All partic ...

[Condensed Interim Consolidated Financial Statements](index=2&type=section&id=Condensed%20Interim%20Consolidated%20Financial%20Statements) This section presents the company's financial position, performance, equity changes, and cash flows for the interim period, highlighting key financial trends and balances [Condensed Interim Consolidated Statements of Financial Position](index=2&type=section&id=CONDENSED%20INTERIM%20CONSOLIDATED%20STATEMENTS%20OF%20FINANCIAL%20POSITION) As of June 30, 2022, total assets decreased to **$40.2 million** from **$45.9 million** at year-end 2021, primarily due to reduced cash and cash equivalents Key Financial Position Data (in CAD) | Financial Item | June 30, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $33,689,255 | $41,262,044 | | Total current assets | $39,407,457 | $44,903,899 | | Total assets | $40,239,327 | $45,880,191 | | **Liabilities & Equity** | | | | Total current liabilities | $2,544,030 | $2,689,838 | | Total liabilities | $9,466,409 | $9,781,206 | | Total shareholders' equity | $30,772,918 | $36,098,985 | | Total liabilities and shareholders' equity | $40,239,327 | $45,880,191 | [Condensed Interim Consolidated Statements of Loss and Comprehensive Loss](index=3&type=section&id=CONDENSED%20INTERIM%20CONSOLIDATED%20STATEMENTS%20OF%20LOSS%20AND%20COMPREHENSIVE%20LOSS) For the six months ended June 30, 2022, net loss improved to **$11.9 million** from **$13.7 million** in the prior year, driven by lower operating expenses and foreign exchange gains Six Months Ended June 30 (in CAD) | Metric | 2022 | 2021 | | :--- | :--- | :--- | | Research and development expenses | $6,911,968 | $5,962,195 | | Operating expenses | $5,444,246 | $6,662,876 | | Foreign exchange gain (loss) | $413,954 | $(1,021,906) | | Net loss | $(11,873,330) | $(13,680,881) | | Net comprehensive loss | $(11,807,827) | $(13,769,563) | | Basic and diluted loss per common share | $(0.21) | $(0.26) | [Condensed Interim Consolidated Statements of Changes in Equity](index=4&type=section&id=CONDENSED%20INTERIM%20CONSOLIDATED%20STATEMENTS%20OF%20CHANGES%20IN%20EQUITY) Shareholders' equity decreased to **$30.8 million** from **$36.1 million** at year-end 2021, primarily due to the net loss, partially offset by ATM proceeds Reconciliation of Shareholders' Equity for Six Months Ended June 30, 2022 (in CAD) | Item | Amount | | :--- | :--- | | Equity at December 31, 2021 | $36,098,985 | | Net loss and other comprehensive income | $(11,807,827) | | Issued pursuant to "At the Market" Agreement | $5,819,149 | | Share-based compensation | $1,129,092 | | Share issue costs | $(478,564) | | Other equity changes | $12,083 | | Equity at June 30, 2022 | $30,772,918 | [Condensed Interim Consolidated Statements of Cash Flows](index=5&type=section&id=CONDENSED%20INTERIM%20CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) Net cash decreased by **$8.0 million** for the six months ended June 30, 2022, with **$13.2 million** used in operations and **$5.2 million** provided by financing activities Cash Flow Summary for Six Months Ended June 30 (in CAD) | Cash Flow Activity | 2022 | 2021 | | :--- | :--- | :--- | | Cash used in operating activities | $(13,169,334) | $(12,365,339) | | Cash used in investing activities | $(47,166) | $(6,598) | | Cash provided by financing activities | $5,170,164 | $33,147,057 | | (Decrease) increase in cash | $(8,046,336) | $20,775,120 | | Cash and cash equivalents, end of period | $33,689,255 | $50,799,432 | [Notes to Condensed Interim Consolidated Financial Statements](index=6&type=section&id=NOTES%20TO%20CONDENSED%20INTERIM%20CONSOLIDATED%20FINANCIAL%20STATEMENTS) This section provides detailed disclosures and explanations supporting the condensed interim consolidated financial statements, covering accounting policies, significant estimates, and financial instrument risks [Note 1: Incorporation and Nature of Operations](index=6&type=section&id=Note%201%3A%20Incorporation%20and%20Nature%20of%20Operations) Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on cancer immunotherapies, with pelareorep as its lead product - The company is a **development-stage biopharmaceutical firm** focused on **cancer immunotherapies**, with its lead product being **pelareorep**, designed for combination treatments[12](index=12&type=chunk) - Management has considered potential impacts from COVID-19 and the conflict in Ukraine, noting **no material impact** as of June 30, 2022, though future periods could be affected[13](index=13&type=chunk) [Note 5: Share Capital](index=8&type=section&id=Note%205%3A%20Share%20Capital) Issued share capital increased due to **2.77 million** shares issued via ATM agreements, raising **$5.8 million**, and a new **US$65 million** ATM agreement was established - The company sold **2,774,685 common shares** through its ATM agreements in the first six months of 2022, raising gross proceeds of **$5,819,149**[22](index=22&type=chunk)[23](index=23&type=chunk) - A new ATM equity distribution agreement was established on June 17, 2022, allowing the company to issue shares with an aggregate offering value of up to **US$65 million**[23](index=23&type=chunk) - Equity warrants for **16,443,500 shares** expired on June 1, 2022, leading to the reclassification of their **$3.6 million** value from 'Warrants' to 'Contributed surplus'[24](index=24&type=chunk)[25](index=25&type=chunk) [Note 6: Share-Based Compensation](index=9&type=section&id=Note%206%3A%20Share-Based%20Compensation) As of June 30, 2022, **5.23 million** stock options were outstanding, and total share-based compensation expense for the six months was **$1.13 million**, a decrease from the prior year Stock Option Activity (Six Months Ended June 30) | Activity | 2022 | 2021 | | :--- | :--- | :--- | | Outstanding, beginning of period | 5,334,420 | 3,764,055 | | Granted | 222,500 | 1,172,500 | | Forfeited/Expired/Exercised | (323,589) | (149,911) | | Outstanding, end of period | 5,233,331 | 4,786,644 | - Share-based compensation expense was **$1,129,092** for the six months ended June 30, 2022, compared to **$1,690,318** for the same period in 2021[30](index=30&type=chunk) [Note 8: Commitments](index=10&type=section&id=Note%208%3A%20Commitments) The company has financial commitments totaling **$17.7 million** over the next three years, primarily for clinical trials, manufacturing, and translational science programs - The company is committed to payments of **$17,683,381** over the next three years for activities related to clinical trials, manufacturing, and science programs[32](index=32&type=chunk) - A significant commitment is the co-development agreement with **Pfizer** for the **BRACELET-1 Phase 2 clinical trial**, which is jointly funded[33](index=33&type=chunk) Undiscounted Lease Liability as at June 30, 2022 (in CAD) | Period | Amount | | :--- | :--- | | Less than one year | $386,669 | | One to five years | $244,077 | | Total | $630,746 | [Note 9: Capital Disclosures](index=11&type=section&id=Note%209%3A%20Capital%20Disclosures) The company manages capital by securing cash for development activities, primarily through equity issuance, and renewed its shelf prospectus to raise up to **$150 million** until July 2024 - The **primary objective** of capital management is to obtain cash resources to support planned activities, mainly through **issuing additional common shares**[37](index=37&type=chunk)[40](index=40&type=chunk) - On June 16, 2022, the company renewed its Base Shelf prospectus, qualifying for the distribution of up to **$150,000,000** of securities in Canada and/or the U.S. until July 2024[41](index=41&type=chunk)[43](index=43&type=chunk) - The Base Shelf allowed the company to enter into a **US$65,000,000** ATM equity distribution agreement in June 2022 to assist in achieving its capital objectives[44](index=44&type=chunk) [Note 10: Financial Instruments](index=12&type=section&id=Note%2010%3A%20Financial%20Instruments) The company's primary financial risk is foreign exchange, with a net **US$24.0 million** position, where a **$0.01** USD/CAD increase would decrease net comprehensive loss by **$256,000** - The company is primarily exposed to **foreign exchange risk** from the **U.S. dollar**, as a portion of financial assets and liabilities are denominated in USD[50](index=50&type=chunk) Significant Balances in Foreign Currencies (USD) at June 30, 2022 | Item | Amount | | :--- | :--- | | Cash and cash equivalents | $24,828,157 | | Accounts payable and accrued liabilities | $(844,588) | | **Net Position** | **$23,983,569** | - **Liquidity risk** is managed through the capital structure, primarily by **raising funds via equity** as outlined in Note 9[53](index=53&type=chunk) [Note 12: Other Expenses and Adjustments](index=15&type=section&id=Note%2012%3A%20Other%20Expenses%20and%20Adjustments) This note details research and development and operating expenses, including **$2.4 million** in R&D employee compensation and **$1.1 million** in operating employee compensation for H1 2022 Expense Breakdown for Six Months Ended June 30 (in CAD) | Expense Component | 2022 | 2021 | | :--- | :--- | :--- | | **Research and development:** | | | | Employee compensation and benefits | $2,364,705 | $1,885,259 | | Share-based compensation | $637,273 | $958,948 | | **Operating expenses:** | | | | Employee compensation and benefits | $1,148,339 | $1,047,950 | | Share-based compensation | $491,819 | $731,370 | [Note 13: Related Party Transactions](index=15&type=section&id=Note%2013%3A%20Related%20Party%20Transactions) Total compensation for key management personnel decreased to **$2.4 million** for the six months ended June 30, 2022, primarily due to lower share-based compensation Key Management Personnel Compensation for Six Months Ended June 30 (in CAD) | Compensation Type | 2022 | 2021 | | :--- | :--- | :--- | | Compensation and short-term benefits | $1,593,069 | $1,556,565 | | Share-based compensation | $769,072 | $1,167,071 | | **Total** | **$2,362,141** | **$2,723,636** |

Oncolytics Biotech, Inc. (NASDAQ:ONCY) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Corporate Participants Jon Patton - Director, Investor Relations and Communications Matthew Coffey - President and Chief Executive Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. Kirk Look - Chief Financial Officer Conference Call Participants John Newman - Canaccord Jason Kolbert - HC Wainwright Operator Good aft ...

Oncolytics Biotech, Inc. (NASDAQ:ONCY) Q4 2021 Earnings Conference Call March 3, 2022 5:00 PM ET Company Participants Jon Patton - Director, IR & Communication Matthew Coffey - President, CEO & Director Thomas Heineman - Chief Medical Officer Kirk Look - CFO Andrew de Guttadauro - Global Head, Business Development & President, Oncolytics Biotech (U.S.) Inc Conference Call Participants Operator Good afternoon, and welcome to Oncolytics Biotech's Fourth Quarter 2021 Conference Call. [Operator Instructions] Pl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...

Financial Data and Key Metrics Changes - Oncolytics Biotech reported financial results for Q3 2021, with specific metrics highlighted in the press release [3]. - The company emphasized its focus on the development and commercialization of pelareorep, a cancer therapeutic [4]. Business Line Data and Key Metrics Changes - The management discussed the ongoing clinical trials related to pelareorep, indicating a strategic focus on expanding its market potential [4]. Market Data and Key Metrics Changes - The company is exploring business development opportunities to enhance pelareorep's market presence [4]. Company Strategy and Development Direction - Oncolytics Biotech's strategy includes a focus on the potential of pelareorep as a cancer treatment, with plans for a registrational study [4]. Management Comments on Operating Environment and Future Outlook - Management provided insights into the anticipated benefits of current clinical trials and the overall business prospects [4]. Other Important Information - The call included a reminder that forward-looking statements were made regarding the company's business prospects and development plans [4]. Q&A Session Summary Question: What are the company's plans regarding pelareorep's market expansion? - Management indicated that they are actively pursuing business development opportunities to expand pelareorep's market potential [4].

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q2 2021 Results Earnings Conference Call August 6, 2021 8:00 AM ET Company Participants Jon Patton - Director, IR and Communication Matt Coffey - President and CEO Tom Heineman - Global Head, Clinical Development and Operations Andrew de Guttadauro - Global Head, Business Development Kirk Look - CFO Conference Call Participants John Newman - Canaccord Patrick Trucchio - H.C. Wainwright Operator Good morning. And welcome to Oncolytics BiotechÂ's Second Quarter 2021 Confe ...